· Published by Health Canada · Official notice
This is duplicated text of a letter from Pharmacia Canada Inc. and Pfizer Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
May 13, 2002
Dear Healthcare Professional,
Pharmacia Canada Inc. and Pfizer Canada Inc., in consultation with Health Canada, would like to bring to your attention changes to the product monograph for Celebrex® (celecoxib) including important findings from the Celecoxib Long Term Arthritis Safety Study (CLASS). Celebrex® is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits the cyclooxygenase-2 (COX-2) enzyme and is indicated for acute and chronic use in the relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA).
A prospective long-term outcome study was conducted in approximately 5800 OA and 2200 RA patients. Patients received Celebrex® 400 mg BID (4-fold and 2-fold greater than the daily recommended 200 mg OA and 400 mg RA doses, respectively), ibuprofen 800 mg TID or diclofenac 75 mg BID (common therapeutic doses for OA and RA) for a median exposure of 9 months for Celebrex® and diclofenac, and 6 months for ibuprofen. The primary endpoint of this outcome study was the incidence of complicated ulcers (gastrointestinal bleeding, perforation or obstruction). Additional protocol specified endpoints included the incidence of symptomatic ulcers (gastroduodenal ulcers identified based on upper gastrointestinal symptoms such as abdominal pain, dyspepsia, nausea, diarrhea or vomiting) and clinically relevant decreases in hemoglobin (greater than 2 g/dl) and/or hematocrit (greater than or equal to 10 points). Patients with cardiovascular risk factors, including those with a recent history of myocardial infarction or stroke and patients deemed to require low-dose acetylsalicylic acid (ASA) for cardiovascular prophylaxis (less than or equal to 325 mg) were included in the study.
No statistically significant differences were demonstrated for the incidence of complicated ulcers at the doses studied among the three treatment groups in all patients.
Secondary analysis showed that the incidence of complicated and symptomatic ulcers was lower for Celebrex® than for ibuprofen, but not for diclofenac, in all patients and in those patients not taking ASA. Approximately 22% of patients were taking low-dose ASA.
Concomitant low-dose ASA use increased the rates of complicated and symptomatic ulcers to four times that of patients not taking ASA.
Celebrex® at the doses studied had a significantly lower incidence of gastrointestinal intolerability compared to diclofenac, but not ibuprofen. Celebrex® demonstrated a significantly lower incidence of clinically relevant decreases in hemoglobin (greater than 2 g/dl) or hematocrit (greater than or equal to 10 points) than either ibuprofen or diclofenac, regardless of ASA use.
In the CLASS study, the rates of hypertension in all patients on Celebrex® 400 mg BID (4-fold and 2-fold the recommended doses for OA and RA), and common therapeutic doses of ibuprofen (800 mg TID) and diclofenac (75 mg BID) were 2.0%, 3.1% and 2.0%, respectively. The corresponding rates for edema were: 3.7%, 5.2% and 3.5%, respectively. The corresponding rates for cardiac failure were: 0.2%, 0.5% and 0.1%, respectively.
The incidence rates of myocardial infarction (fatal and non-fatal) in all patients including those taking ASA for cardiovascular prophylaxis were: 0.5% for Celebrex® 400 mg BID, 0.5% for ibuprofen 800 mg TID, and 0.2% for diclofenac 75 mg BID. The corresponding rates for patients not taking ASA were: 0.2%, 0.1%, and 0.1% respectively.
The adverse event profile from the CLASS study was similar to those reported in the arthritis-controlled trials. No significant differences were seen across treatment groups in the incidences of serious adverse events.
The following standard Contraindications set by Health Canada for all NSAIDs have been added to the Product Monograph for Celebrex®:
The information summarized below has been previously available in Product Monograph for Celebrex®, and is provided here as an important reminder to ensure optimal prescribing:
Pharmacia Canada Inc. and Pfizer Canada Inc. are committed to providing you with the most current product information available for the management of your patients receiving Celebrex®. Celebrex® provides a safe and effective treatment for OA and RA patients when prescribed according to the Product Monograph. An updated Celebrex® Product Monograph is available at: www.pharmacia.ca.
The identification, characterization, and management of drug-related adverse events are dependent on the active participation of health care professionals in adverse drug reaction reporting programmes. Any occurrences of adverse events in patients receiving Celebrex® should be reported to:
Pharmacia Canada Inc.
55 Standish Court, Suite 1200
Mississauga, Ontario L5R 4E3
Attention: Director, Medical Information and Drug Safety
Your professional commitment in this regard has an important role in protecting the well-being of your patients by contributing to early signal detection and informed drug use.
If you have any questions or require additional information on Celebrex®, please call the Pharmacia Medical Information Department at 1 800 268-7888.
Sincerely,
original signed by
David Cook, MD
Vice President, Medical & Scientific Affairs
Pharmacia Canada Inc.
original signed by
Bernard Prigent, MD
Vice President & Medical Director
Pfizer Canada Inc.
Any suspected adverse reactions can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0201C2
Ottawa, Ontario, K1A 1B9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The ADR Reporting Form can be found in The Canadian Compendium of Pharmaceuticals and Specialties, or on the TPD website, along with the ADR Guidelines.